"Allopurinol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.
| Descriptor ID |
D000493
|
| MeSH Number(s) |
D03.633.100.759.160
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Allopurinol".
Below are MeSH descriptors whose meaning is more specific than "Allopurinol".
This graph shows the total number of publications written about "Allopurinol" by people in this website by year, and whether "Allopurinol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 2 | 4 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Allopurinol" by people in Profiles.
-
Preston WA, Pace DJ, Altshuler PJ, Yi M, Kittle HD, Vincent SA, Andreoni KA, Frank AM, Glorioso JM, Ramirez CG, Maley WR, Shah AP, Bodzin AS. A propensity score matched analysis of liver transplantation outcomes in the setting of preservation solution shortage. Am J Transplant. 2024 Apr; 24(4):619-630.
-
Abhishek A, Cipolletta E, Nakafero G, Avery AJ, Mamas M, Tata LJ. Serum urate outcomes of treat-to-target urate lowering treatment: results of a nationwide cohort study from 1997 to the COVID-19 pandemic using data from the Clinical Practice Research Datalink. Ann Rheum Dis. 2022 12; 81(12):1768-1769.
-
Battula NR, Andreoni KA. Oxygenated Preservation Solutions for Organ Preservation. Transplantation. 2019 02; 103(2):233-234.
-
Jutkowitz E, Alarid-Escudero F, Choi HK, Kuntz KM, Jalal H. Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. Pharmacoeconomics. 2017 Oct; 35(10):1073-1085.
-
Jutkowitz E, Dubreuil M, Lu N, Kuntz KM, Choi HK. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum. 2017 04; 46(5):594-600.
-
Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015 May 19; 131(20):1763-71.
-
Jutkowitz E, Choi HK, Pizzi LT, Kuntz KM. Cost-effectiveness of allopurinol and febuxostat for the management of gout. Ann Intern Med. 2014 Nov 04; 161(9):617-26.
-
Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD. Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014 Nov 04; 161(9):659-67.
-
DuPont JJ, Ramick MG, Farquhar WB, Townsend RR, Edwards DG. NADPH oxidase-derived reactive oxygen species contribute to impaired cutaneous microvascular function in chronic kidney disease. Am J Physiol Renal Physiol. 2014 Jun 15; 306(12):F1499-506.
-
Meltzer M. Allopurinol versus rilonacept for the prevention of gout flares: comment on the article by Schumacher et al. Arthritis Care Res (Hoboken). 2013 May; 65(5):838.